^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    temuterkib (LY3214996)

    i
    Company:
    Eli Lilly
    Drug class:
    ERK2 inhibitor, ERK1 inhibitor
    Related drugs:
    Apply
    Targeted Pathway Inhibition in Patients With Pancreatic Cancer (NCT04005690)
    Phase 1
    OHSU Knight Cancer Institute
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    08/01/2019
    Primary completion :
    06/01/2026
    Completion :
    02/01/2028
    UGT1A1 • CD4
    |
    UGT1A1*1*1
    |
    Lynparza (olaparib) • Cotellic (cobimetinib) • Imjudo (tremelimumab-actl) • onvansertib (PCM-075) • azenosertib (ZN-c3) • saruparib (AZD5305) • temuterkib (LY3214996)
    Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) (KEYNOTE E27) (NCT04956640)
    Phase 1/2
    Eli Lilly and Company
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    07/19/2021
    Primary completion :
    06/01/2026
    Completion :
    06/01/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • erlotinib • carboplatin • Tyvyt (sintilimab) • Verzenio (abemaciclib) • pemetrexed • batoprotafib (TNO155) • temuterkib (LY3214996) • LY3295668 • olomorasib (LY3537982)
    LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer (NCT04616183)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/30/2024
    Initiation :
    12/02/2020
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    KRAS • BRAF • MAP2K1
    |
    Erbitux (cetuximab) • Verzenio (abemaciclib) • temuterkib (LY3214996) • Datalai (cetuximab biosimilar)
    LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients (NCT04391595)
    Phase 1
    Nader Sanai
    Recruiting
    Last update posted :
    03/27/2024
    Initiation :
    07/08/2020
    Primary completion :
    12/01/2024
    Completion :
    02/01/2025
    CDKN2A • CDK4 • CDKN2B
    |
    CDK4 amplification
    |
    Verzenio (abemaciclib) • temuterkib (LY3214996)
    A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer (NCT02857270)
    Phase 1
    Eli Lilly and Company
    Completed
    Last update posted :
    11/22/2022
    Initiation :
    09/29/2016
    Primary completion :
    02/10/2021
    Completion :
    10/24/2022
    BRAF • NRAS
    |
    BRAF V600E • NRAS mutation • BRAF V600 • RAS mutation
    |
    Erbitux (cetuximab) • gemcitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Braftovi (encorafenib) • temuterkib (LY3214996) • midazolam hydrochloride
    Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA) (NCT04916236)
    Phase 1
    The Netherlands Cancer Institute
    Recruiting
    Last update posted :
    06/03/2022
    Initiation :
    03/31/2022
    Primary completion :
    01/31/2024
    Completion :
    07/01/2024
    EGFR • KRAS • PIK3CA • MET • PTEN • HRAS
    |
    vociprotafib (RMC-4630) • temuterkib (LY3214996)
    ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies (NCT04043845)
    Phase 1
    Dana-Farber Cancer Institute
    Withdrawn
    Last update posted :
    02/05/2020
    Initiation :
    02/03/2020
    Primary completion :
    02/03/2020
    Completion :
    02/03/2020
    PLCG2
    |
    Imbruvica (ibrutinib) • temuterkib (LY3214996)